Roche CEO Hopes For Progress As China Tackles Approval Lag
This article was originally published in PharmAsia News
Recent signs that China is aiming to speed up its lengthy drug review processes are “encouraging” but there is still more to be done towards implementing “good and robust regulatory science” in the country, says Roche CEO Severin Schwan.
You may also be interested in...
In a statement submitted to the Senate Finance Committee, Natural Products Association CEO Dan Fabricant suggests two ways of improving compliance with new dietary ingredient notification requirements at negligible expense to the US FDA.
Public Company Edition: Legend Biotech raised $424m in its US public market debut. Also, Pfizer commits up to $500m for equity investments and Allogene capitalizes on ASCO with a $550m offering.
US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.